ALK and non-small cell lung carcinoma: In 120 ALK-positive NSCLC patients continuing crizotinib beyond initial progression (51% with brain progression), longer median survival was reported compared with patients who received other chemotherapy (16.4 vs. 5.4 months) (135), although this benefit could also be related to local therapies and more indolent disease in the crizotinib arm.